ClinicalTrials.gg
WithdrawnNCT02746328Updated Feb 26, 2024

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

A Phase 2 interventional study of GTx-024 9 or 18 mg in ER+ and AR+ Breast Cancer, sponsored by GTx. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-26.

Sponsored by GTx · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Investigational drug development was halted.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

This is a multiple site, proof of concept feasibility study to describe the effect of GTx-024 9 or 18 mg on physical function in female subjects, from protocol G200802, with ER+/AR+ breast cancer.

02

Conditions studied

  • ER+ and AR+ Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Lead sponsor

GTx is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In screening for, and ultimately randomized into, protocol G200802
  2. Give voluntary, written and signed, for this add-on study
  3. Age 18 to 70 years old
  4. Physically capable of mounting and riding a stationary bicycle
  5. Subject agrees to not significantly alter physical activity or current physical training during the study period

Exclusion criteria

Exclusion Criteria:

  1. Subject has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases subject risk, in the opinion of the Investigator
  2. Subjects unwilling to or unable to comply with the protocol
  3. Any other condition which per investigators' judgement may increase subject risk
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    GTx-024 9 or 18 mg

    Patients enrolled in G200802 receiving GTx-024 9 or 18 mg

    Drug: GTx-024 9 or 18 mg

Interventions

  • Patients enrolled in G200802 receiving GTx-024 9 or 18 mg

    Also known as: Enobosarm

06

What researchers measure

Primary outcomes

  1. Maximal Power Production

    Describe the effect of 24 weeks of treatment of GTx-024 on maximal power production as assessed by inertial-load cycle ergometry

    Time frame: 24 Weeks

Secondary outcomes

  1. Maximal Power Production

    Describe the effect of 12 weeks of treatment of GTx-024 on maximal power production as assessed by inertial-load cycle ergometry

    Time frame: 12 Weeks

  2. Lean Body Mass

    Describe the effect of 24 weeks of treatment of GTx-024 on lean body mass (LBM) as assessed by CT images of the lumbar region from L3 to the iliac crest

    Time frame: 24 Weeks

  3. Lean Body Mass

    Describe the effect of 12 weeks of treatment of GTx-024 on LBM as assessed by CT images of the lumbar region from L3 to the iliac crest

    Time frame: 12 Weeks

  4. Maximal Power Production, Scaled to Total Body Mass

    Describe the effect of 24 weeks of treatment of GTx-024 on maximal power production scaled (Watts/kilogram) to total body mass (TBM), as assessed by inertial-load cycle ergometry

    Time frame: 24 Weeks

  5. Maximal Power Production, Scaled to Lean Body Mass

    Describe the effect of 24 weeks of treatment of GTx-024 on maximal power production scaled (Watts/kilogram) to LBM, as assessed by inertial-load cycle ergometry

    Time frame: 24 Weeks

  6. Optimal Pedaling Rate

    Describe the effect of 24 weeks of treatment of GTx-024 on optimal pedaling rate

    Time frame: 24 Weeks

Other outcomes

  1. Exploratory Objective

    Describe the impact of baseline measures and measures obtained throughout the study on maximal power production and its change from baseline

    Time frame: 24 Weeks

07

Study locations

1 site
  • University of Washington, School of Medicine
    Seattle, Washington 98109, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Feb 2018 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2016
First posted
Apr 21, 2016
Start
Apr 2016
Primary completionActual
Feb 2018
CompletionActual
Feb 2018
Last update
Feb 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02746328
Lead sponsor
GTx
Responsible party
Sponsor
First posted
Apr 21, 2016
Start date
Apr 2016
Primary completion
Feb 2018
Completion
Feb 2018
Last update
Feb 26, 2024

Study contacts

Hannah M Linden, MD
principal investigator · University of Washington

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion